<DOC>
	<DOC>NCT02338349</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of RAD1901 in patients with advanced ER+, HER2-negative breast cancer.</brief_summary>
	<brief_title>A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer</brief_title>
	<detailed_description>The primary objective is to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of RAD1901 in patients with advanced ER+HER2-negative breast cancer. The secondary objectives of this study are: - To assess the safety and tolerability of RAD1901 - To evaluate the pharmacokinetics (PK) of RAD1901 - To evaluate the preliminary anti-tumor effect of RAD1901</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>1. Patients must be postmenopausal women, as defined in the protocol 2. 18 years or older 3. Patients with histological or cytological proven diagnosis of adenocarcinoma of the breast with evidence of either locally advanced, inoperable and/or metastatic disease 4. Patients must have received no more than 2 prior chemotherapeutic regimens and at least 6 months of prior endocrine therapy 1. Prior anticancer or investigational drug treatment within the following windows: 1. Tamoxifen therapy less than 14 days before first dose of study treatment 2. Fulvestrant therapy less than 90 days before first dose of study treatment 3. Any other anticancer endocrine therapy less than 14 days before first dose of study treatment 4. Any chemotherapy less than 28 days before first dose of study 5. Any investigational drug therapy less than 28 days or 3 halflives (whichever is longer) prior to first dose of study treatment 2. Patients with untreated or symptomatic central nervous system (CNS) metastases 3. Patients with endometrial disorders, including evidence of endometrial hyperplasia, dysfunctional uterine bleeding or cysts</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>